Replimune Group Inc (REPL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Replimune Group Inc (REPL) Earnings: Report Dates and Results
Replimune Group (REPL) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, Replimune Group reported EPS of -$0.54, above the -$0.70 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
REPL has an expected report date of Feb 1, 2027.
REPL Earnings Call
The latest REPL earnings call transcript on file is labeled 2025Q4.
Read the 2025Q4 transcriptEarnings History
Of the 34 quarters below that had an estimate, REPL beat 12, missed 19 and matched 3. The widest gap in the table came in the quarter ended Jun 30, 2018, when EPS landed 778.26% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.54 | -$0.70 | N/A | +22.86% | Beat | N/A | 2 | 0 up, 0 down | Oct 28, 2026 |
| Jun 30, 2026 | -$0.72 | -$0.72 | N/A | 0.00% | In line | N/A | 3 | 0 up, 1 down | Aug 14, 2026 |
| Mar 31, 2026 | -$0.76 | -$0.73 | N/A | -4.11% | Miss | N/A | 4 | 0 up, 0 down | Jun 29, 2026 |
| Dec 31, 2025 | -$0.77 | -$0.82 | -$0.93 - -$0.71 | +6.10% | Beat | N/A | 5 | 3 up, 1 down | Feb 3, 2026 |
| Sep 30, 2025 | -$0.90 | -$0.79 | -$0.89 - -$0.70 | -13.92% | Miss | N/A | 5 | 2 up, 1 down | Nov 6, 2025 |
| Jun 30, 2025 | -$0.95 | -$0.83 | -$0.90 - -$0.66 | -14.46% | Miss | N/A | 6 | 0 up, 1 down | Aug 7, 2025 |
| Mar 31, 2025 | -$0.82 | -$0.69 | -$0.74 - -$0.64 | -18.84% | Miss | N/A | 3 | 1 up, 1 down | May 22, 2025 |
| Dec 31, 2024 | -$0.79 | -$0.72 | -$0.73 - -$0.71 | -9.72% | Miss | N/A | 2 | 0 up, 0 down | Feb 12, 2025 |
| Sep 30, 2024 | -$0.68 | -$0.74 | -$0.83 - -$0.69 | +8.11% | Beat | N/A | 7 | 0 up, 0 down | Nov 12, 2024 |
| Jun 30, 2024 | -$0.78 | -$0.83 | -$1.10 - -$0.70 | +6.02% | Beat | N/A | 8 | 0 up, 0 down | Aug 8, 2024 |
| Mar 31, 2024 | -$0.25 | -$0.80 | -$0.86 - -$0.70 | +68.75% | Beat | N/A | 8 | 0 up, 0 down | May 16, 2024 |
| Dec 31, 2023 | -$0.77 | -$0.93 | -$1.01 - -$0.85 | +17.20% | Beat | N/A | 8 | 0 up, 0 down | Feb 8, 2024 |
| Sep 30, 2023 | -$0.90 | -$0.89 | -$0.99 - -$0.80 | -1.12% | Miss | N/A | 9 | 0 up, 0 down | Nov 7, 2023 |
| Jun 30, 2023 | -$0.75 | -$0.84 | -$0.93 - -$0.80 | +10.71% | Beat | N/A | 7 | 1 up, 0 down | Aug 3, 2023 |
| Mar 31, 2023 | -$0.74 | -$0.66 | -$0.78 - -$0.59 | -12.12% | Miss | N/A | 8 | 2 up, 0 down | May 18, 2023 |
| Dec 31, 2022 | -$0.69 | -$0.74 | -$0.84 - -$0.63 | +6.76% | Beat | N/A | 9 | 0 up, 0 down | Feb 9, 2023 |
| Sep 30, 2022 | -$0.79 | -$0.76 | -$0.85 - -$0.74 | -3.95% | Miss | N/A | 9 | 0 up, 0 down | Nov 3, 2022 |
| Jun 30, 2022 | -$0.78 | -$0.56 | N/A | -39.29% | Miss | N/A | N/A | 0 up, 0 down | Aug 4, 2022 |
| Mar 31, 2022 | -$0.60 | -$0.60 | -$0.65 - -$0.46 | 0.00% | In line | N/A | 10 | 0 up, 0 down | May 19, 2022 |
| Dec 31, 2021 | -$0.57 | -$0.57 | -$0.63 - -$0.52 | 0.00% | In line | N/A | 10 | 0 up, 0 down | Feb 3, 2022 |
| Sep 30, 2021 | -$0.56 | -$0.52 | -$0.61 - -$0.50 | -7.69% | Miss | N/A | 8 | N/A | Nov 4, 2021 |
| Jun 30, 2021 | -$0.53 | -$0.42 | -$0.52 - -$0.34 | -26.19% | Miss | N/A | 8 | N/A | Aug 6, 2021 |
| Mar 31, 2021 | -$0.41 | -$0.38 | -$0.48 - -$0.34 | -7.89% | Miss | N/A | 7 | N/A | May 20, 2021 |
| Dec 31, 2020 | -$0.42 | -$0.41 | -$0.47 - -$0.36 | -2.44% | Miss | N/A | 8 | N/A | Feb 4, 2021 |
| Sep 30, 2020 | -$0.46 | -$0.44 | -$0.49 - -$0.40 | -4.55% | Miss | N/A | 8 | N/A | Nov 5, 2020 |
| Jun 30, 2020 | -$0.44 | -$0.43 | -$0.51 - -$0.41 | -2.33% | Miss | N/A | 6 | N/A | Aug 7, 2020 |
| Mar 31, 2020 | -$0.41 | -$0.45 | -$0.49 - -$0.39 | +8.89% | Beat | N/A | 7 | N/A | Jun 3, 2020 |
| Dec 31, 2019 | -$0.46 | -$0.36 | -$0.43 - -$0.31 | -27.78% | Miss | N/A | 5 | N/A | Feb 13, 2020 |
| Sep 30, 2019 | -$0.35 | -$0.34 | -$0.41 - -$0.26 | -2.94% | Miss | N/A | 7 | N/A | Nov 11, 2019 |
| Jun 30, 2019 | -$0.30 | -$0.31 | -$0.45 - -$0.25 | +3.23% | Beat | N/A | 6 | N/A | Aug 14, 2019 |
| Mar 31, 2019 | -$0.15 | -$0.40 | -$0.58 - -$0.33 | +62.50% | Beat | N/A | 4 | N/A | Jun 28, 2019 |
| Dec 31, 2018 | -$0.24 | -$0.25 | -$0.25 - -$0.23 | +4.00% | Beat | N/A | 3 | N/A | Feb 14, 2019 |
| Sep 30, 2018 | -$0.26 | -$0.19 | N/A | -36.84% | Miss | N/A | N/A | N/A | Nov 14, 2018 |
| Jun 30, 2018 | -$2.02 | -$0.23 | -$0.24 - -$0.21 | -778.26% | Miss | N/A | 3 | N/A | Jul 23, 2018 |
| Mar 31, 2018 | -$0.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 11, 2018 |
Annual EPS
EPS for the fiscal year ended Mar 31, 2026 was -$3.38, after -$3.07 the year before. It was -$0.42 for the year ended Mar 31, 2018, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Mar 31, 2026 | -$3.38 | N/A |
| Mar 31, 2025 | -$3.07 | N/A |
| Mar 31, 2024 | -$2.67 | N/A |
| Mar 31, 2023 | -$3.00 | N/A |
| Mar 31, 2022 | -$2.26 | N/A |
| Mar 31, 2021 | -$1.73 | N/A |
| Mar 31, 2020 | -$1.52 | N/A |
| Mar 31, 2019 | -$2.67 | N/A |
| Mar 31, 2018 | -$0.42 | N/A |
Earnings Calls
The only earnings call listed below, 2025Q4 for the period ended Dec 31, 2025, runs about 4,900 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q4 | Dec 31, 2025 | 4,884 | 11 |
2025Q4 Earnings Call
Opening remarks
Arleen Goldenberg Introduction Thank you, Operator, and good morning, everyone. Thank you for joining us today for a discussion of Replimune's fiscal year fourth quarter 2025 business highlights and financial results. Leading the call today will be Sushil Patel, our Chief Executive Officer. He will be joined by Chris Sarchi, our Chief Commercial Officer, and Emily Hill, our Chief Financial Officer. After our prepared remarks, we will open the call for Q&A. An audio recording and webcast replay for today's conference call will also be available online as detailed in the press release announcement for this call. During today's call, we will be making certain forward-looking statements, including, without limitations, statements about the potential safety, efficacy, and regulatory and clinical progress of our product candidates, our anticipated cash runway, and our future expectations, plans, partnerships, and prospects. These statements are subject to various risks such as changes in market conditions and difficulties associated with research and development and regulatory approval processes. These and other risk factors are described in the filings made with the SEC, including our annual report on Form 10-K and our Form 10-Q filed today. Forward-looking statements are based on the assumptions, opinions, and estimates of management at the date the statements are made, including the non-occurrence of the risk and uncertainties that are described in the filings made with the SEC or other significant events occurring outside of Replimune's normal course of business. You are cautioned not to place undue reliance on these forward-looking statements, which are made as of today, May 22, 2025. Replimune disclaims any obligation to update such statements, even if management's views change, except as required by law. With that, let me turn the call over to Sushil Patel, Replimune's Chief Executive Officer.
Sushil Patel CEO Thank you, Arleen, and welcome everyone to today's earnings call. We appreciate you joining us as we review our fiscal fourth quarter and full year 2025 results. Today, we'll highlight the significant progress we've made across regulatory, clinical, and commercial as we approach the potential approval and launch of RP1. You'll also hear updates on our confirmatory Ignite 3 trial, pipeline developments for RP2, and our financial position as we prepare for commercial readiness. I'll begin with a strategic overview before turning the call over to Chris to walk through launch preparation and Emily to cover our financials. Replimune was founded to pioneer the next generation of oncolytic immunotherapy and is now poised to realize that promise with a substantial body of evidence supporting our mission. In particular, data from the Ignite Study shows that roughly one-third of patients are able to achieve a durable response in a high unmet need setting with few options.
Frequently Asked Questions About REPL
When is Replimune Group's next earnings date?
Replimune Group's next earnings report is expected for Feb 1, 2027.
Did REPL beat earnings estimates last quarter?
Yes. Replimune Group reported EPS of -$0.54 for the quarter ended Sep 30, 2026, above the -$0.70 estimate, a 22.86% surprise.
What EPS do analysts expect from REPL next quarter?
The consensus EPS estimate for Replimune Group for the quarter ending Dec 31, 2026 is -$0.47 from 4 analysts, with estimates from -$0.49 to -$0.45.
How often does REPL beat earnings estimates?
Replimune Group beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -4.01%.
REPL pages: Overview, Earnings, Forecast, Financials, Competitors